FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/12/2026
Back to search
Official data from USPTO
SAMJIN SAMJIN PHARM.
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
24
Latest update
04/03/2026
Trademark type
Combined
Nice classes
5
Filing date
07/04/2024
Registration date
06/24/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/24/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
KR
Examiner
KOPENSKI, CLAUDIA ANN
Law office
O20
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of an oval filled with green. Inside the oval, the bold word "SAMJIN" is written in white, next to it are the bold words "SAMJIN PHARM" in black and a period mark in bold black.
Holders and representatives
Holders
Samjin Pharmaceutical Co., Ltd.
Samjin Pharmaceutical Co., Ltd. 1
Representatives
Jae Youn Kim NKL Law
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for health care for treating of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorder; vitamin and mineral dietary supplements; vitamin supplements; crude medicines for relieving anxietytensiondyspepsiaobesitypainhypertensioninsomniadiabetes; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; nutraceuticals for use as a dietary supplement; pharmaceutical drugs in the nature of antiviral pharmaceuticalsantibacterial pharmaceuticalspsychiatric pharmaceuticalsoncological pharmaceuticalssurgical pharmaceuticals; analgesics; probiotic supplements
Publications
History of USPTO decisions and trademark events.
24 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/25/2026
FIMP
FINAL DISPOSITION PROCESSED
01/25/2026
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
01/25/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/24/2025
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
08/01/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/24/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
06/24/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/06/2025
PUBO
PUBLISHED FOR OPPOSITION
05/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/30/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/02/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/30/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/30/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/30/2025
RFNT
REFUSAL PROCESSED BY IB
03/01/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/10/2025
RFRR
REFUSAL PROCESSED BY MPU
02/10/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/03/2025
CNRT
NON-FINAL ACTION WRITTEN
01/02/2025
DOCK
ASSIGNED TO EXAMINER
12/28/2024
MAFR
APPLICATION FILING RECEIPT MAILED
08/22/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/22/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/22/2024
Continuous trademark protection
Get notified about every new filing that threatens SAMJIN SAMJIN PHARM. or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.